| Literature DB >> 17184535 |
Deborah E Turner1, Philip S Helliwell, Paul Emery, James Woodburn.
Abstract
BACKGROUND: Foot involvement occurs early in rheumatoid arthritis but the extent to which this impacts on the structure and function leading to impairment and foot related disability is unknown. The purpose of this study was to compare clinical disease activity, impairment, disability, and foot function in normal and early rheumatoid arthritis (RA) feet using standardised clinical measures and 3D gait analysis.Entities:
Mesh:
Year: 2006 PMID: 17184535 PMCID: PMC1764742 DOI: 10.1186/1471-2474-7-102
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Demographic, clinical and foot impairment/disability scores for 12 RA patients and normal reference values for 12 age and sex matched able-bodied adults
| 1/43/L | MTX | 30.5 | 7.3 | - | 14 | 19 | 14 | 14 | 4 | 1 | 0 | -5 valgus |
| 2/48/R | - | 26.3 | 6.2 | - | 11 | 12 | 11 | 5 | 3 | 0 | 0 | 6 varus |
| 3/36/R | SSZ | 19.5 | 5.5 | - | 17 | 23 | 8 | 12 | 5 | 3 | 0 | -4 valgus |
| 4/55/L | MTX | 27.4 | 5.0 | + | 6 | 8 | 0 | 2 | 0 | 2 | 1 | -9 valgus |
| 5/50/R | - | 27.0 | 4.1 | - | 11 | 14 | 9 | 9 | 2 | 0 | 0 | -4 valgus |
| 6/27/R | MTX | 25.1 | 4.1 | Missing | 9 | 10 | 1 | 9 | 2 | 0 | 1 | -8 valgus |
| 7/44/L | MTX, SSZ, HCQ | 35.1 | 3.7 | - | 11 | 6 | 0 | 1 | 0 | 5 | 0 | -2 valgus |
| 8/32/R | TNFα, MTX | 21.9 | 3.4 | - | 12 | 22 | 0 | 7 | 4 | 9 | 2 | -7 valgus |
| 9/58/R | MTX | 25.0 | 2.7 | - | 10 | 3 | 1 | 10 | 1 | 0 | 0 | -6 valgus |
| 10/60/L | MTX | 38.9 | 2.5 | + | 10 | 15 | 0 | 1 | 0 | 6 | 2 | 7 varus |
| 11/43/R | SSZ | 28.5 | 2.3 | + | 7 | 5 | 0 | 3 | 1 | 10 | 1 | -8 valgus |
| 12/63/L | MTX, HCQ | 32.0 | 2.3 | - | 10 | 7 | 0 | 0 | 0 | 2 | 2 | -9 valgus |
| Median 46 | - | 27.2 | 3.9 | 11 | 11 | 1 | 6 | 2 | 2 | 1 | -6 valgus | |
| Range 27–63 | - | 19.5–35.1 | 2.3–7.3 | 6–17 | 3–23 | 0–14 | 0–14 | 0–5 | 0–10 | 0–2 | -9 valgus-7 varus | |
| Median 47 | - | 23.7 | - | - | 1 | 0 | 0 | 0 | 0 | 1 | 0 | -3 valgus |
| Range 27–64 | - | 19.1–31.8 | - | - | 0–4 | 0–2 | 0–2 | 0–1 | 0 | 0–2 | 0–2 | -8 valgus-1 varus |
DMARD = disease-modifying antirheumatic drug; MTX = methotrexate; SSZ = sulphasalazine; HCQ = hydroxychloroquine; TNFα = tumour necrosing factor α blockade; BMI = body mass index; DAS28 = disease activity score using 28 joint counts; LFISIF = Leeds Foot Impact Scale-Impairment/Footwear subscale score 9 range 0–21); LFISAP = Leeds Foot Impact Scale-Activity Limitation/Participation Restriction subscale score (range 0–30); SJC = swollen joint count (range 0–14); TJC = tender joint count (range 0–14); PJC = painful joint count (range 0–14); SIFF = structural index for forefoot; SIRF = structural index for rearfoot. RSFP = relaxed standing foot posture.
Gait characteristics in patients with early rheumatoid arthritis and age and sex matched able-bodied adults
| Walking speed (m/s) | 1.30 (0.17) | 1.05 (0.20) | -0.24 | (-0.41, -0.08) | |
| Double-support (%GC) | 15.8 (3.4) | 19.3 (4.7) | 3.5 | (0, 7.0) | |
| Initial foot contact angle (deg) | 13.8 (2.4) | 14.2 (4.5) | -0.4 | (-3.5, 2.7) | |
| Terminal stance heel rise (deg) | -85.7 (5.4) | -78.9 (9.6) | 6.7 | (0.1, 13.5) | |
| Minimum arch height (mm) | 31 (5) | 29 (7) | -2 | (-8, 3) | |
| Peak eversion (deg) | -4.4 (3.4) | -5.5 (9.8) | -1.1 | (-7.5, 5.4) | |
| Peak force loading response (BW) | 1.11 (0.12) | 1.05 (0.12) | -0.07 | (-0.17, 0.04) | |
| Peak force terminal stance (BW) | 1.12 (0.62) | 1.12 (0.61) | 0 | (-0.05, 0.05) | |
| Peak plantarflexion moment (Nm/kg) | -1.6 (0.1) | -1.5 (0.1) | 0 | (-0.1, 0.1) | |
| Peak ankle joint power (W/kg) | 4.6 (1.6) | 3.4 (1.0) | -1.3 | (-2.4, 0.2) | |
| CoP at 50% foot length (% stance) | 44.2 (5.0) | 44.3 (10.8) | 0.1 | (-7.2, 7.4) | |
| Lesser toes contact area (cm-2) | 8.1 (1.9) | 7.6 (3.1) | -0.5 | (-2.7, 1.7) | |
| Midfoot contact area (cm-2) | 19.4 (6.5) | 24.6 (7.2) | 5.3 | (-0.6, 11.1) | |
| Forefoot peak pressure (kPa) | 553 (193) | 672 (255) | 119 | (-73, 311) |
CI = confidence interval; BW = body weight (vertical ground reaction force normalised to body weight)
Figure 1Selected gait parameters normalised for 100% stance (each graph is individually scaled and the gray band represents the mean ± 1 SD for the able-bodied adults and the solid line is the mean ± 1 SD error bars for the RA patients. A – Initial foot-to-floor and terminal stance heel rise angles during stance, measured as the angle of the plantar surface of the foot to the horizontal. Positive angles decreasing to zero indicate increasing foot-to-floor contact, zero indicates foot flat, and increasing negative angles indicate progressive heel rise; B – frontal plane motion of the rearfoot in the shank coordinate system during stance phase (+ inversion/- eversion); C – ground reaction forces normalised to body mass acting perpendicular to the plantar aspect of the foot; D – sagittal plane ankle joint power during stance).